Other explored variables, including gender, site of metastatic disease, the extent of metastatic disease, previous resection of the bowel cancer primary, and the number of lines of therapy did not have a significant influence on the benefit associated with EGFR mAb in patients in KRAS WT mCRC. Here, KRAS is linked to intestinal cancer.